Potential Molecular and Cellular Mechanism of Psychotropic Drugs

키워드

참고문헌 (137)

1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR" (2000), American Psychiatric Association
2. Kessler RC, "Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 62, pp.617~627 (2005)
3. Surja AA, "Antipsychotic medications in the treatment of bipolar disorder", Curr Drug Targets, 7, pp.1217~1224 (2006)
4. Belmaker RH, "Bipolar disorder: Treatment", Discov Med, 4, pp.415~420 (2004)
5. Goodwin FK, "Manic-depressive illness:bipolar disorders and recurrent depression" (2007), Oxford University Press
6. Tandon R, "Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia", Schizophr Res, 100, pp.20~38 (2008)
7. Roth TL, "Epigenetic mechanisms in schizophrenia", Biochim Biophys Acta, 1790, pp.869~877 (2009)
8. Oh G, "Environmental studies of schizophrenia through the prism of epigenetics", Schizophr Bull, 34, pp.1122~1129 (2008)
9. Gavin DP, "Histone modifications, DNA methylation, and schizophrenia", Neurosci Biobehav Rev, 34, pp.882~888 (2010)
10. Bird A., "DNA methylation patterns and epigenetic memory", Genes Dev, 16, pp.6~21 (2002)
11. Miranda TB, "DNA methylation: the nuts and bolts of repression", J Cell Physiol, 213, pp.384~390 (2007)
12. Klose RJ, "Genomic DNA methylation: the mark and its mediators", Trends Biochem Sci, 31, pp.89~97 (2006)
13. Luger K, "Characterization of nucleosome core particles containing histone proteins made in bacteria", J Mol Biol, 272, pp.301~311 (1997)
14. Brownell JE, "Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation", Cell, 84, pp.843~851 (1996)
15. Hegi ME, "MGMT gene silencing and benefit from temozolomide in glioblastoma", N Engl J Med, 352, pp.997~1003 (2005)
16. Klose RJ, "Regulation of histone methylation by demethylimination and demethylation", Nat Rev Mol Cell Biol, 8, pp.307~318 (2007)
17. Shimabukuro M, "Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats", Behav Brain Funct, 2, pp.37~ (2006)
18. Guidotti A, "Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study", Arch Gen Psychiatry, 57, pp.1061~1069 (2000)
19. Benes FM, "Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars", Proc Natl Acad Sci U S A, 104, pp.10164~10169 (2007)
20. Fatemi SH, "Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression", Mol Psychiatry, 5, pp.654~663 (2000)
21. Abdolmaleky HM, "Hypermethylation of the reelin (RELN)promoter in the brain of schizophrenic patients: a preliminary report", Am J Med Genet B Neuropsychiatr Genet, 134B, pp.60~66 (2005)
22. Grayson DR, "Reelin promoter hypermethylation in schizophrenia", Proc Natl Acad Sci U S A, 102, pp.9341~9346 (2005)
23. Costa E, "GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability", Expert Rev Neurother, 9, pp.87~98 (2009)
24. Dong E, "Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation", Proc Natl Acad Sci U S A, 105, pp.13614~13619 (2008)
25. Kim SH, "Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells", Life Sci, 91, pp.1317~1322 (2012)
26. Melas PA, "Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset", FASEB J, 26, pp.2712~2718 (2012)
27. Li J, "Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling", J Neurochem, 90, pp.1117~1131 (2004)
28. Bertran-Gonzalez J, "Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons", Neuropsychopharmacology, 34, pp.1710~1720 (2009)
29. Kurita M, "HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2promoter activity", Nat Neurosci, 15, pp.1245~1254 (2012)
30. Ookubo M, "Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL", 6 mice: Brain region specific changes, 2013, pp.47, 1204~1214
31. Marks PA, "Histone deacetylase inhibitors", Adv Cancer Res, 91, pp.137~168 (2004)
32. Tremolizzo L, "Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice", Biol Psychiatry, 57, pp.500~509 (2005)
33. Leng Y, "Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity", J Neurosci, 26, pp.7502~7512 (2006)
34. Perisic T, "Valproate and amitriptyline exert common and divergent influences on global and gene promoterspecific chromatin modifications in rat primary astrocytes", Neuropsychopharmacology, 35, pp.792~805 (2010)
35. D'Addario C, "Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII", Neuropsychopharmacology, 37, pp.1647~1655 (2012)
36. Asai T, "Effect of mood stabilizers on DNA methylation in human neuroblastoma cells", Int J Neuropsychopharmacol, 16, pp.2285~2294 (2013)
37. Sugawara H, "Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins", Transl Psychiatry, 1, pp.e24~ (2011)
38. Huzayyin AA, "Decreased global methylation in patients with bipolar disorder who respond to lithium", Int J Neuropsychopharmacol, 17, pp.561~569 (2014)
39. Tsankova NM, "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action", Nat Neurosci, 9, pp.519~525 (2006)
40. Cassel S, "Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain", Mol Pharmacol, 70, pp.487~492 (2006)
41. Zimmermann N, "Antidepressants inhibit DNA methyltransferase 1through reducing G9a levels", Biochem J, 448, pp.93~102 (2012)
42. Melas PA, "Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression", Int J Neuropsychopharmacol, 15, pp.669~679 (2012)
43. Svenningsson P, "Alterations in 5-HT1B receptor function by p11 in depression-like states", Science, 311, pp.77~80 (2006)
44. Anisman H, "Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects", J Psychiatry Neurosci, 33, pp.131~141 (2008)
45. Van Sant SP, "Pharmacotherapy for treatmentrefractory schizophrenia", Expert Opin Pharmacother, 12, pp.411~434 (2011)
46. Guidotti A, "Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling", Trends Pharmacol Sci, 30, pp.55~60 (2009)
47. Matrisciano F, "Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain", Mol Pharmacol, 80, pp.174~182 (2011)
48. Roth BL, "Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia", Nat Rev Drug Discov, 3, pp.353~359 (2004)
49. Missale C, "Dopamine receptors: from structure to function", Physiol Rev, 78, pp.189~225 (1998)
50. Beaulieu JM, "The physiology, signaling, and pharmacology of dopamine receptors", Pharmacol Rev, 63, pp.182~217 (2011)
51. Conley RR, "Treatment of the special patient with schizophrenia", Dialogues Clin Neurosci, 3, pp.123~135 (2001)
52. Joober R, "Clozapine: a distinct, poorly understood and under-used molecule", J Psychiatry Neurosci, 35, pp.147~149 (2010)
53. Zorn SH, "Clozapine is a potent and selective muscarinic M4 receptor agonist", Eur J Pharmacol, 269, pp.R1~R2 (1994)
54. Olianas MC, "Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4receptor", Br J Pharmacol, 122, pp.401~408 (1997)
55. Mailman RB, "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?", Curr Pharm Des, 16, pp.488~501 (2010)
56. cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain, "J Pharmacol Exp Ther", 2002, 197~209
57. Turalba AV, "Antipsychotics regulate cyclic AMP-dependent protein kinase and phospho rylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice", Neurosci Lett, 357, pp.53~57 (2004)
58. Svenningsson P, "DARPP-32: an integrator of neurotransmission", Annu Rev Pharmacol Toxicol, 44, pp.269~296 (2004)
59. Pozzi L, "Opposite regulation by typical and atypical anti-psychotics of ERK1", 2, CREB and Elk-1phosphorylation in mouse dorsal striatum., 2003, pp.86, 451~459
60. Bateup HS, "Cell type-specific regulation of DARPP-32phosphorylation by psychostimulant and antipsychotic drugs", Nat Neurosci, 11, pp.932~939 (2008)
61. Bibb JA, "Phosphorylation of DARPP-32 by Cdk5modulates dopamine signalling in neurons", Nature, 402, pp.669~671 (1999)
62. Valjent E, "Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32", Neuropsychopharmacology, 36, pp.2561~2570 (2011)
63. Sutherland C, "Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling", Biochem J, 296, pp.15~19 (1993)
64. Emamian ES, "Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia", Nat Genet, 36, pp.131~137 (2004)
65. Aubry JM, "Early effects of mood stabilizers on the Akt", GSK-3beta signaling pathway and on cell survival and proliferation, 2009, pp.205, 419~429
66. 노명선, "Haloperidol and clozapine differentially regulate signalsupstream of glycogen synthase kinase 3 in the rat frontal cortex", Experimental and Molecular Medicine, 39(3), pp.353~360 (2007), 생화학분자생물학회
67. Réus GZ, "The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain", J Psychiatr Res, 46, pp.1029~1035 (2012)
68. Cadigan KM, "Wnt signaling: a common theme in animal development", Genes Dev, 11, pp.3286~3305 (1997)
69. Alimohamad H, "The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats", J Neurochem, 95, pp.513~525 (2005)
70. Sutton LP, "Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3", J Neurochem, 102, pp.153~169 (2007)
71. Kang UG, "The effects of clozapine on the GSK-3-mediated signaling pathway", FEBS Lett, 560, pp.115~119 (2004)
72. Sweatt JD, "Genetics of childhood disorders: LI. Learning and memory, Part 4: Human cognitive disorders and the ras", ERK, J Am Acad Child Adolesc Psychiatry, pp.2003, 42[DOI]
73. Fumagalli F, "Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex", Mol Pharmacol, 69, pp.1366~1372 (2006)
74. Ahmed MR, "Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation", J Pharmacol Exp Ther, 325, pp.276~283 (2008)
75. Kim SH, "Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex", Int J Neuropsychopharmacol, 11, pp.509~517 (2008)
76. Kim SH, "Role of MKP-1 (DUSP1) in clozapine-induced effects on the ERK1", 2 signaling pathway in the rat frontal cortex, 2013, pp.230, 425~437
77. Pereira A, "Clozapine induction of ERK1", 2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs, 2012, pp.15, 1149~1160
78. Pereira A, "Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor", J Mol Neurosci, 39, pp.185~198 (2009)
79. Pereira A, "Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum", Prog Neuropsychopharmacol Biol Psychiatry, 40, pp.353~363 (2013)
80. Jope RS., "Anti-bipolar therapy: mechanism of action of lithium", Mol Psychiatry, 4, pp.117~128 (1999)
81. Liang MH, "Lithium inhibits Smad3", 4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling, 2008, pp.37, 440~453
82. Cechinel-Recco K, "Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania", J Psychopharmacol, 26, pp.1594~1604 (2012)
83. Gallagher HC, "Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6glioma G1 phase progression", Neurotoxicol Teratol, 26, pp.73~81 (2004)
84. Montezinho LP, "Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors", Bipolar Disord, 9, pp.290~297 (2007)
85. Chang P, "Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP", Epilepsia, 51, pp.1533~1542 (2010)
86. Beaulieu JM, "Lithium antagonizes dopamine-dependent behaviors mediated by an AKT", glycogen synthase kinase 3 signaling cascade, 2004, pp.101, 5099~5104
87. Ryves WJ, "Lithium inhibits glycogen synthase kinase-3 by competition for magnesium", Biochem Biophys Res Commun, 280, pp.720~725 (2001)
88. Grimes CA, "CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium", J Neurochem, 78, pp.1219~1232 (2001)
89. Gould TD, "In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3", Neuropsychopharmacology, 29, pp.32~38 (2004)
90. Wexler EM, "Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation", Mol Psychiatry, 13, pp.285~292 (2008)
91. De Sarno P, "Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium", Neuropharmacology, 43, pp.1158~1164 (2002)
92. Roh MS, "Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine", Biol Psychiatry, 57, pp.278~286 (2005)
93. Mai L, "BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents", J Neurochem, 82, pp.75~83 (2002)
94. Di Daniel E, "Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons", Bipolar Disord, 7, pp.33~41 (2005)
95. Yuan PX, "The mood stabilizer valproic acid activates mitogen- activated protein kinases and promotes neurite growth", J Biol Chem, 276, pp.31674~31683 (2001)
96. Einat H, "The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.", J Neurosci, 23, pp.7311~7316 (2003)
97. Casu MA, "Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens", Brain Res, 1141, pp.15~24 (2007)
98. Young C, "Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain", Neurobiol Dis, 31, pp.355~360 (2008)
99. Longoni R, "The MEK inhibitor SL327 blocks acquisition but not expression of lithium- induced conditioned place aversion: a behavioral and immunohistochemical study", Psychopharmacology (Berl), 216, pp.63~73 (2011)
100. Kim SH, "Egr1 regulates lithium-induced transcription of the Period 2 (PER2) gene", Biochim Biophys Acta, 1832, pp.1969~1979 (2013)
101. Plante DT, "Sleep disturbance in bipolar disorder: therapeutic implications", Am J Psychiatry, 165, pp.830~843 (2008)
102. Jensen JB, "Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatment", Eur Neuropsychopharmacol, 10, pp.105~111 (2000)
103. Thome J, "cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment", J Neurosci, 20, pp.4030~4036 (2000)
104. Tiraboschi E, "Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades", Neuropsychopharmacology, 29, pp.1831~1840 (2004)
105. Wang Z, "Effect of chronic stress on PKA and P-CREB expression in hippocampus of rats and the antagonism of antidepressors", Zhong Nan Da Xue Xue Bao Yi Xue Ban, 31, pp.767~771 (2006)
106. Takano K, "Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes", J Pharmacol Sci, 120, pp.176~186 (2012)
107. Li X, "In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain", Neuropsychopharmacology, 29, pp.1426~1431 (2004)
108. Basta-Kaim A, "Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K", AKT mediated pathway, 2005, pp.49, 156~164
109. Huang W, "Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1", 2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1, J Mol Neurosci, pp.2013, 49[DOI]
110. Mostany R, "A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation", Neuropharmacology, 55, pp.18~26 (2008)
111. Pinnock SB, "The roles of BDNF, pCREB and Wnt3a in the latent period preceding activation of progenitor cell mitosis in the adult dentate gyrus by fluoxetine", PLoS One, 5, pp.e13652~ (2010)
112. Pilar-Cuéllar F, "Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain- derived neurotrophic factor, β-catenin and antidepressant-like effects", Br J Pharmacol, 165, pp.1046~1057 (2012)
113. Fumagalli F, "Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1", 2 phosphorylation in rat brain, 2005, pp.93, 1551~1560
114. Di Benedetto B, "Acute antidepressant treatment differently modulates ERK", MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex, 2012, pp.(12), S0306~S4522
115. First M, "The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression", J Mol Neurosci, 45, pp.246~255 (2011)
116. Qi X, "Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress", Neurobiol Dis, 31, pp.278~285 (2008)
117. Hisaoka K, "Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells", J Pharmacol Exp Ther, 321, pp.148~157 (2007)
118. Hisaoka K, "Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: a possible contribution to GDNF production", Brain Res, 1196, pp.53~58 (2008)
119. Chekulaeva M, "Mechanisms of miRNAmediated post-transcriptional regulation in animal cells", Curr Opin Cell Biol, 21, pp.452~460 (2009)
120. Soifer HS, "MicroRNAs in disease and potential therapeutic applications", Mol Ther, 15, pp.2070~2079 (2007)
121. Xu B, "MicroRNAs in psy chiatric and neurodevelopmental disorders", Brain Res, 1338, pp.78~88 (2010)
122. Perkins DO, "microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder", Genome Biol, 8, pp.R27~ (2007)
123. Kocerha J, "MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction.", Proc Natl Acad Sci U S A, 106, pp.3507~3512 (2009)
124. Santarelli DM, "Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine", Psychopharmacology (Berl), 227, pp.67~78 (2013)
125. Gardiner E, "Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes", Int J Neuropsychopharmacol, 17, pp.929~943 (2014)
126. Newcomer JW., "Antipsychotic medications: metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl 4), pp.8~13 (2007)
127. Miljevic C, "Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.303~307 (2010)
128. Zhou R, "Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers", Neuropsychopharmacology, 34, pp.1395~1405 (2009)
129. Shibata H, "Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia", Psychiatry Res, 167, pp.88~96 (2009)
130. Creson TK, "Lithium treatment attenuates muscarinic M(1) receptor dysfunction.", Bipolar Disord, 13, pp.238~249 (2011)
131. Chen H, "MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment", Int J Neuropsychopharmacol, 12, pp.975~981 (2009)
132. Hunsberger JG, "Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases:identifying associations and functions", Am J Transl Res, 5, pp.450~464 (2013)
133. Millan MJ., "MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues", Curr Opin Pharmacol, 11, pp.11~22 (2011)
134. Baudry A, "miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants", Science, 329, pp.1537~1541 (2010)
135. Launay JM, "Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16", Transl Psychiatry, 1, pp.e56~ (2011)
136. Angelucci F, "Paroxetine rapidly modulates the expression of brain-derived neurotrophic factor mRNA and protein in a human glioblastoma-astrocytoma cell line", Pharmacology, 87, pp.5~10 (2011)
137. Bocchio-Chiavetto L, "Blood microRNA changes in depressed patients during antidepressant treatment", Eur Neuropsychopharmacol, 23, pp.602~611 (2013)

관련 논문AI추천